Respiratory syncytial virus infection in adults

The BMJ

Volumn 366, Issue , 2019, Pages

  Nam, Hannah H ^a   Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALX 017 1; ANTIVIRUS AGENT; ASVASIRAN; BTA 9881; CODAGENIX; EDP 938; ENZAPLATOVIR; JNJ 53718678; JNJ 64417184; LIVE VACCINE; LUMICITABINE; MEISSA VACCINE; PALIVIZUMAB; PC 786; PRESATOVIR; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; RV 521; UNCLASSIFIED DRUG; VIRUS VACCINE; ZIRESOVIR; IMMUNOGLOBULIN;

ANTIGEN DETECTION; COMORBIDITY; DISEASE BURDEN; DISEASE TRANSMISSION; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; LOWER RESPIRATORY TRACT INFECTION; MORTALITY RATE; PATHOGENESIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; SYSTEMATIC REVIEW; VIROLOGY; ADULT; EPIDEMIC; GENETICS; GENOTYPE; GLOBAL DISEASE BURDEN; IMMUNOLOGY; PATHOGENICITY; PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; SEASON;

ADULT; ANTIVIRAL AGENTS; EPIDEMICS; GENOTYPE; GLOBAL BURDEN OF DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; RIBAVIRIN; SEASONS;

EID: 85072015699     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.l5021     Document Type: Review

References (189)

1. Afonso CL, Amarasinghe GK, Bányai K, et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 2016;161:2351-60. doi:10.1007/s00705-016-2880-1
2. Rima B, Collins P, Easton A, et al, Ictv Report Consortium. ICTV Virus Taxonomy Profle: Pneumoviridae. J Gen Virol 2017;98:2912-3. doi:10.1099/jgv.0.000959
3. Chanock R, Finberg L. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 1957;66:291-300.
4. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-Analysis. Lancet 2010;375:1545-55. doi:10.1016/S0140-6736(10) 60206-1
5. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;352:1749-59. doi:10.1056/NEJMoa043951
6. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Influenza-And respiratory syncytial virus-Associated mortality and hospitalisations. Eur Respir J 2007;30:1158-66. doi:10.1183/09031936.00034407
7. Shi T, Denouel A, Tietjen AK, et al, RESCEU Investigators. Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. J Infect Dis 2019;jiz059. doi:10.1093/infdis/jiz059
8. Taleb SA, Al Thani AA, Al Ansari K, Yassine HM. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis 2018;37:1817-27. doi:10.1007/s10096-018-3289-4
9. Bashir U, Alam MM, Sadia H, Zaidi SS, Kazi BM. Molecular characterization of circulating respiratory syncytial virus (RSV) genotypes in Gilgit Baltistan Province of Pakistan during 2011-2012 winter season. PLoS One 2013;8:e74018. doi:10.1371/journal. pone.0074018
10. Al-Toum R, Bdour S, Ayyash H. Epidemiology and clinical characteristics of respiratory syncytial virus infections in Jordan. J Trop Pediatr 2006;52:282-7. doi:10.1093/tropej/fml002
11. DeVincenzo J P, McClure MW, Symons JA, et al. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study. N Engl J Med 2015;373:2048-58. doi:10.1056/NEJMoa1413275
12. Grifths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev 2017;30:277-319. doi:10.1128/CMR.00010-16
13. Martinello RA, Chen MD, Weibel C, Kahn JS. Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis 2002;186:839-42. doi:10.1086/342414
14. Espinosa Y, San Martín C, Torres AA, et al. Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants. Int J Mol Sci 2017;18:654. doi:10.3390/ijms18030654
15. Grad YH, Newman R, Zody M, et al. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol 2014;88:7286-93. doi:10.1128/JVI.00038-14
16. Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-Analysis. J Clin Microbiol 2015;53:3738-49. doi:10.1128/JCM.01816-15
17. Binder W, Thorsen J, Borczuk P. RSV in adult ED patients: Do emergency providers consider RSV as an admission diagnosis?Am J Emerg Med 2017;35:1162-5. doi:10.1016/j.ajem.2017.06.022
18. Colosia AD, Yang J, Hillson E, et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review. PLoS One 2017;12:e0182321. doi:10.1371/journal.pone.0182321
19. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28. doi:10.1056/NEJM200106213442507
20. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86. doi:10.1001/jama.289.2.179
21. Jain S, Self WH, Wunderink RG, et al, CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015;373:415-27. doi:10.1056/NEJMoa1500245
22. Widmer K, Zhu Y, Williams JV, Grifn MR, Edwards KM, Talbot HK. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis 2012;206:56-62. doi:10.1093/infdis/jis309
23. Widmer K, Grifn MR, Zhu Y, Williams JV, Talbot HK. Respiratory syncytial virus-And human metapneumovirus-Associated emergency department and hospital burden in adults. Influenza Other Respir Viruses 2014;8:347-52. doi:10.1111/irv.12234
24. Falsey AR, McElhaney JE, Beran J, et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014;209:1873-81. doi:10.1093/infdis/jit839
25. Beckhaus AA, Castro-Rodriguez JA. Down Syndrome and the Risk of Severe RSV Infection: A Meta-Analysis. Pediatrics 2018;142:e20180225. doi:10.1542/peds.2018-0225
26. Chatzis O, Darbre S, Pasquier J, et al. Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study. BMC Infect Dis 2018;18:111. doi:10.1186/s12879-018-3002-3
27. Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Efect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics 2006;117:349-56. doi:10.1542/peds.2004-2795
28. Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults. J Am Coll Cardiol 2018;71:1574-83. doi:10.1016/j.jacc.2018.02.013
29. Weinberg A, Lyu DM, Li S, Marquesen J, Zamora MR. Incidence and morbidity of human metapneumovirus and other community-Acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis 2010;12:330-5. doi:10.1111/j.1399-3062.2010.00509.x
30. Milstone AP, Brumble LM, Barnes J, et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006;28:131-7. doi:10.1183/09031936.06.00105505
31. Choi EH, Lee HJ, Chanock SJ. Human genetics and respiratory syncytial virus disease: current fndings and future approaches. Curr Top Microbiol Immunol 2013;372:121-37. doi:10.1007/978-3-642-38919-1-6
32. Gan SW, Ng L, Lin X, Gong X, Torres J. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Sci 2008;17:813-20. doi:10.1110/ps.073366208
33. Walsh EE, Hall CB. Respiratory syncytial virus (RSV). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 8th ed. El Sevier, 2015: 1948-60.
34. Colman PM, Lawrence MC. The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 2003;4:309-19. doi:10.1038/nrm1076
35. Krzyzaniak MA, Zumstein MT, Gerez JA, Picotti P, Helenius A. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog 2013;9:e1003309. doi:10.1371/journal.ppat.1003309
36. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 2013;372:83-104. doi:10.1007/978-3-642-38919-1-4
37. Vekemans J, Moorthy V, Giersing B, et al. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine 2018;S0264-410X(17)31364-6. doi:10.1016/j. vaccine.2017.09.092
38. Cullen LM, Schmidt MR, Morrison TG. The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV. Hum Vaccin Immunother 2017;13:2814-23. doi:10.1080/21645515.2017.13 29069
39. Anderson LJ, Hierholzer JC, Tsou C, et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985;151:626-33. doi:10.1093/infdis/151.4.626
40. Pangesti KNA, Abd El Ghany M, Walsh MG, Kesson AM, Hill-Cawthorne GA. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol 2018;28. doi:10.1002/rmv.1968
41. Fuentes S, Coyle EM, Beeler J, Golding H, Khurana S. Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifes Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins. PLoS Pathog 2016;12:e1005554. doi:10.1371/journal.ppat.1005554
42. Hall CB, Douglas RGJr. Modes of transmission of respiratory syncytial virus. J Pediatr 1981;99:100-3. doi:10.1016/S0022-3476(81)80969-9
43. Hall CB. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Infect Dis 2000;31:590-6. doi:10.1086/313960
44. French CE, McKenzie BC, Coope C, et al, Noso-RSV Study Group. Risk of nosocomial respiratory syncytial virus infection and efectiveness of control measures to prevent transmission events: a systematic review. Influenza Other Respir Viruses 2016;10:268-90. doi:10.1111/irv.12379
45. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Updated 2019. https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf.
46. Agah R, Cherry JD, Garakian AJ, Chapin M. Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections. Routine isolation procedure vs routine procedure supplemented by use of masks and goggles. Am J Dis Child 1987;141:695-7. doi:10.1001/archpedi.1987.04460060111049
47. Hall CB, Douglas RGJr. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used?Am J Dis Child 1981;135:512-5. doi:10.1001/archpedi.1981.02130300012006
48. Murphy D, Todd JK, Chao RK, Orr I, McIntosh K. The use of gowns and masks to control respiratory illness in pediatric hospital personnel. J Pediatr 1981;99:746-50. doi:10.1016/S0022-3476(81)80401-5
49. Leclair JM, Freeman J, Sullivan BF, Crowley CM, Goldmann DA. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med 1987;317:329-34. doi:10.1056/NEJM198708063170601
50. Sokol KA, De la Vega-Diaz I, Edmondson-Martin K, et al. Masks for prevention of respiratory viruses on the BMT unit: results of a quality initiative. Transpl Infect Dis 2016;18:965-7. doi:10.1111/tid.12608
51. Sung AD, Sung JAM, Thomas S, et al. Universal Mask Usage for Reduction of Respiratory Viral Infections Afer Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 2016;63:999-1006. doi:10.1093/cid/ciw451
52. Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant 2010;16:1265-71. doi:10.1016/j.bbmt.2010.03.011
53. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specifc to ciliated cells, and without obvious cytopathology. J Virol 2002;76:5654-66. doi:10.1128/JVI.76.11.5654-5666.2002
54. Damasio GA, Pereira LA, Moreira SD, Duarte dos Santos CN, Dalla-Costa LM, Raboni SM. Does virus-bacteria coinfection increase the clinical severity of acute respiratory infection?J Med Virol 2015;87:1456-61. doi:10.1002/jmv.24210
55. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specifc to ciliated cells, and without obvious cytopathology. J Virol 2002;76:5654-66. doi:10.1128/JVI.76.11.5654-5666.2002
56. McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child 2003;88:922-6. doi:10.1136/adc.88.10.922
57. Garcia-Mauriño C, Moore-Clingenpeel M, Thomas J, et al. Viral Load Dynamics and Clinical Disease Severity in Infants With Respiratory Syncytial Virus Infection. J Infect Dis 2019;219:1207-15. doi:10.1093/infdis/jiy655
58. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-34. doi:10.1093/oxfordjournals.aje.a120955
59. Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001;82:2881-8. doi:10.1099/0022-1317-82-12-2881
60. Graham BS. Vaccine development for respiratory syncytial virus. Curr Opin Virol 2017;23:107-12. doi:10.1016/j.coviro.2017.03.012
61. Habibi MS, Jozwik A, Makris S, et al, Mechanisms of Severe Acute Influenza Consortium Investigators. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med 2015;191:1040-9. doi:10.1164/rccm.201412-2256OC
62. Brandenburg AH, Groen J, van Steensel-Moll HA, et al. Respiratory syncytial virus specifc serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997;52:97-104. doi:10.1002/(SICI)1096-9071(199705)52:13.0.CO;2-Y
63. Murphy BR, Graham BS, Prince GA, et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 1986;23:1009-14.
64. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006;78:1493-7. doi:10.1002/jmv.20724
65. Tripp RA, Power UF, Openshaw PJM, Kauvar LM. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. J Virol 2018;92:e01302-17.
66. Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. Modifcation of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J Virol 2014;88:10165-76. doi:10.1128/JVI.01250-14
67. Welliver T P, Reed JL, Welliver RCSr. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J 2008;27(Suppl):S92-6. doi:10.1097/INF.0b013e318168b706
68. Hegele RG, Hayashi S, Hogg JC, Paré PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995;151:1659-64, discussion 1664-5. doi:10.1164/ajrccm/151.5-Pt-1.1659
69. Cho CH, Lee CK, Nam M-H, et al. Evaluation of the AdvanSure™ real-time RT-PCR compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses. Diagn Microbiol Infect Dis 2014;79:14-8. doi:10.1016/j.diagmicrobio.2014.01.016
70. Liao RS, Tomalty LL, Majury A, Zoutman DE. Comparison of viral isolation and multiplex real-time reverse transcription-PCR for confrmation of respiratory syncytial virus and influenza virus detection by antigen immunoassays. J Clin Microbiol 2009;47:527-32. doi:10.1128/JCM.01213-08
71. Popow-Kraupp T, Aberle JH. Diagnosis of respiratory syncytial virus infection. Open Microbiol J 2011;5:128-34. doi:10.2174/1874285 801105010128
72. Salez N, Nougairede A, Ninove L, Zandotti C, de Lamballerie X, Charrel RN. Prospective and retrospective evaluation of the Cepheid Xpert® Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus. Diagn Microbiol Infect Dis 2015;81:256-8. doi:10.1016/j.diagmicrobio.2015.01.008
73. Popowitch EB, Miller MB. Performance Characteristics of Xpert Flu/RSV XC Assay. J Clin Microbiol 2015;53:2720-1. doi:10.1128/JCM.00972-15
74. Gharabaghi F, Hawan A, Drews SJ, Richardson SE. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect 2011;17:1900-6. doi:10.1111/j.1469-0691.2011.03529.x
75. Gadsby NJ, Hardie A, Claas ECJ, Templeton KE. Comparison of the Luminex Respiratory Virus Panel fast assay with in-house real-time PCR for respiratory viral infection diagnosis. J Clin Microbiol 2010;48:2213-6. doi:10.1128/JCM.02446-09
76. Landry ML, Ferguson D. Comparison of Simplexa Flu A/B & RSV PCR with cytospin-immunofluorescence and laboratory-developed TaqMan PCR in predominantly adult hospitalized patients. J Clin Microbiol 2014;52:3057-9. doi:10.1128/JCM.00738-14
77. Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis 2010;50:747-51. doi:10.1086/650486
78. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol 2002;40:817-20. doi:10.1128/JCM.40.3.817-820.2002
79. Casiano-Colón AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J Clin Virol 2003;28:169-74. doi:10.1016/S1386-6532(03)00002-7
80. Schwartz RH, Selvarangan R, Zissman EN. BD Veritor System Respiratory Syncytial Virus Rapid Antigen Detection Test: Point-of-Care Results in Primary Care Pediatric Ofces Compared With Reverse Transcriptase Polymerase Chain Reaction and Viral Culture Methods. Pediatr Emerg Care 2015;31:830-4. doi:10.1097/PEC.0000000000000371
81. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging 2015;32:261-9. doi:10.1007/s40266-015-0258-9
82. Lieberman D, Shimoni A, Shemer-Avni Y, Keren-Naos A, Shtainberg R, Lieberman D. Respiratory viruses in adults with community-Acquired pneumonia. Chest 2010;138:811-6. doi:10.1378/chest.09-2717
83. Branche AR, Walsh EE, Formica MA, Falsey AR. Detection of respiratory viruses in sputum from adults by use of automated multiplex PCR. J Clin Microbiol 2014;52:3590-6. doi:10.1128/JCM.01523-14
84. Blaschke AJ, McKevitt M, Ampofo K, et al. A Mid-Turbinate Swab Appears Comparable to Nasopharyngeal Swabs for Quantitative Detection of RSV in Infants. Open Forum Infect Dis 2017;4(Suppl 1):S354-5. doi:10.1093/ofd/ofx163.857
85. Centers for Disease Control and Prevention. FDA-cleared RT-PCR assays and other molecular assays for influenza viruses. 2018. https://www.cdc.gov/flu/pdf/professionals/diagnosis/table1-molecular-Assays.pdf.
86. Wald TG, Miller BA, Shult P, Drinka P, Langer L, Gravenstein S. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons?J Am Geriatr Soc 1995;43:170-4. doi:10.1111/j.1532-5415.1995.tb06384.x
87. Falsey AR, Criddle MC, Walsh EE. Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. J Clin Virol 2006;35:46-50. doi:10.1016/j.jcv.2005.04.004
88. Self WH, Williams DJ, Zhu Y, et al. Respiratory Viral Detection in Children and Adults: Comparing Asymptomatic Controls and Patients With Community-Acquired Pneumonia. J Infect Dis 2016;213:584-91. doi:10.1093/infdis/jiv323
89. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000;13:371-84. doi:10.1128/CMR.13.3.371
90. Sundaram ME, Meece JK, Sifakis F, Gasser RAJr, Belongia EA. Medically attended respiratory syncytial virus infections in adults aged = 50 years: clinical characteristics and outcomes. Clin Infect Dis 2014;58:342-9. doi:10.1093/cid/cit767
91. Walsh EE, Peterson DR, Falsey AR. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?J Infect Dis 2007;195:1046-51. doi:10.1086/511986
92. Ariza-Heredia EJ, Fishman JE, Cleary T, Smith L, Razonable RR, Abbo L. Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single-center experience. Transpl Infect Dis 2012;14:64-71. doi:10.1111/j.1399-3062.2011.00673.x
93. Lee N, Lui GC, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013;57:1069-77. doi:10.1093/cid/cit471
94. Schifer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections afer myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009;94:1101-8. doi:10.3324/haematol.2008.003186
95. Boeckh M, Englund J, Li Y, et al, NIAID Collaborative Antiviral Study Group. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007;44:245-9. doi:10.1086/509930
96. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014;209:1195-204. doi:10.1093/infdis/jit832
97. Timbrook T, Maxam M, Bosso J. Antibiotic Discontinuation Rates Associated with Positive Respiratory Viral Panel and Low Procalcitonin Results in Proven or Suspected Respiratory Infections. Infect Dis Ther 2015;4:297-306. doi:10.1007/s40121-015-0087-5
98. Cohen R, Babushkin F, Geller K, Finn T. Characteristics of hospitalized adult patients with laboratory documented Influenza A, B and Respiratory Syncytial Virus-A single center retrospective observational study. PLoS One 2019;14:e0214517. doi:10.1371/journal.pone.0214517
99. Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD 2013;10:293-9. doi:10.3109/15412555.2012.744741
100. Loubet P, Lenzi N, Valette M, et al, FLUVAC Study Group. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. Clin Microbiol Infect 2017;23:253-9. doi:10.1016/j.cmi.2016.11.014
101. Volling C, Hassan K, Mazzulli T, et al. Respiratory syncytial virus infection-Associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis 2014;14:665. doi:10.1186/s12879-014-0665-2
102. Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995;172:389-94. doi:10.1093/infdis/172.2.389
103. Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980;96:179-86. doi:10.1016/S0022-3476(80)80799-2
104. Volling C, Hassan K, Mazzulli T, et al. Respiratory syncytial virus infection-Associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis 2014;14:665. doi:10.1186/s12879-014-0665-2
105. Manuel O, Estabrook MAmerican Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019: e13511 10.1111/ctr.13511
106. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014;59(Suppl 5):S344-51. doi:10.1093/cid/ciu623
107. Waghmare A, Campbell A P, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis 2013;57:1731-41. doi:10.1093/cid/cit639
108. Chemaly RF, Ghosh S, Bodey G P, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85:278-87. doi:10.1097/01. md.0000232560.22098.4e
109. Ljungman P. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014;209:1151-2. doi:10.1093/infdis/jit833
110. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011;117:2755-63. doi:10.1182/blood-2010-08-263400
111. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008;46:402-12. doi:10.1086/525263
112. Shah D P, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodefciency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014;123:3263-8. doi:10.1182/blood-2013-12-541359
113. Weigt SS, Gregson AL, Deng JC, Lynch JP3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011;32:471-93. doi:10.1055/s-0031-1283286
114. López-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation 2007;84:851-6. doi:10.1097/01.tp.0000282788.70383.8b
115. Belperio JA, Weigt SS, Fishbein MC, Lynch JP3rd. Chronic lung allograf rejection: mechanisms and therapy. Proc Am Thorac Soc 2009;6:108-21. doi:10.1513/pats.200807-073GO
116. Broadbent L, Groves H, Shields MD, Power UF. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses 2015;9:169-78. doi:10.1111/irv.12313
117. Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA 1983;249:2666-70. doi:10.1001/jama.1983.03330430042027
118. Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983;72:613-8.
119. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med 1996;150:942-7. doi:10.1001/archpedi.1996.02170340056011
120. Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016;18:210-5. doi:10.1111/tid.12510
121. Chemaly RF, Aitken SL, Wolfe CR, Jain R, Boeckh MJ. Aerosolized ribavirin: the most expensive drug for pneumonia. Transpl Infect Dis 2016;18:634-6. doi:10.1111/tid.12551
122. Trang T P, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative efectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. Transpl Infect Dis 2018;20:e12844. doi:10.1111/tid.12844
123. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000;25:751-5. doi:10.1038/sj.bmt.1702228
124. McCarthy AJ, Kingman HM, Kelly C, et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation. Bone Marrow Transplant 1999;24:1315-22. doi:10.1038/sj.bmt.1702078
125. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia afer marrow transplantation. Antimicrob Agents Chemother 1996;40:2555-7. doi:10.1128/AAC.40.11.2555
126. Nichols WG, Gooley T, Boeckh M. Community-Acquired respiratory syncytial virus and parainfluenza virus infections afer hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001;7(Suppl):11S-5S. doi:10.1053/bbmt.2001. v7.pm11777098
127. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis 2014;59(Suppl 5):S344-51. doi:10.1093/cid/ciu623
128. Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis 2012;206:1367-71. doi:10.1093/infdis/jis516
129. Foolad F, Aitken SL, Shigle TL, et al. Oral versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplantation Recipients. Clin Infect Dis 2018.
130. Marcelin JR, Wilson JW, Razonable RRMayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014;16:242-50. doi:10.1111/tid.12194
131. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013;56:258-66. doi:10.1093/cid/cis844
132. Zaia J, Baden L, Boeckh MJ, et al, Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Disease Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Diseases Canada, Centers for Disease Control and Prevention. Viral disease prevention afer hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:471-82. doi:10.1038/bmt.2009.258
133. Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-efective treatment for respiratory syncytial virus infection afer lung transplantation. J Heart Lung Transplant 2005;24:2114-9. doi:10.1016/j.healun.2005.06.027
134. Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection afer lung transplantation: Efcacy and cost-efciency. J Heart Lung Transplant 2015;34:958-62. doi:10.1016/j. healun.2015.01.009
135. Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection afer lung transplantation. J Heart Lung Transplant 2012;31:839-44. doi:10.1016/j.healun.2012.04.002
136. Pelaez A, Lyon GM, Force SD, et al. Efcacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009;28:67-71. doi:10.1016/j.healun.2008.10.008
137. Shah D P, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013;68:1872-80. doi:10.1093/jac/dkt111
138. Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007;26:1089-93. doi:10.1097/INF.0b013e3181343b7e
139. Seo S, Campbell A P, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: signifcance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013;19:589-96. doi:10.1016/j.bbmt.2012.12.019
140. Falsey AR, Koval C, DeVincenzo JP, Walsh EE. Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons. Transpl Infect Dis 2017;19. doi:10.1111/tid.12657
141. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America, American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-Acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72. doi:10.1086/511159
142. Woodhead M, Blasi F, Ewig S, et al, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-80. doi:10.1183/09031936. 05.00055705
143. DeVincenzo J P, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010;182:1305-14. doi:10.1164/rccm.201002-0221OC
144. Battles MB, Langedijk J P, Furmanova-Hollenstein P, et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol 2016;12:87-93. doi:10.1038/nchembio.1982
145. DeVincenzo J P, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014;371:711-22. doi:10.1056/NEJMoa1401184
146. Gottlieb J, Torres F, Haddad T, et al. A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients. J Heart Lung Transplant 2018;37:S155. doi:10.1016/j. healun.2018.01.375.
147. Hanfelt-Goade D, Maimon N, Nimer A, et al. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial of Presatovir (GS-5806), a Novel Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Hospitalized Adults. American Thoracic Society 2018 International Conference, San Diego, 2018: abstract A4457.
148. Beigel JH, Nam HH, Adams PL, et al. Advances in respiratory virus therapeutics-A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 2019;167:45-67. doi:10.1016/j. antiviral.2019.04.006
149. Stevens M, Rusch S, DeVincenzo J, et al. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis 2018;218:748-56. doi:10.1093/infdis/jiy227
150. Martinon-Torres F, Remmerie B, Rusch S, et al. 1958. Antiviral Efects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678) in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005. Open Forum Infect Dis 2018;5(suppl 1):S566-7. doi:10.1093/ofd/ofy210.1614
151. DeVicenzo T, Tait D, Oluwayi O, et al. Safety and Efcacy of Oral RV521 in a Human Respiratory Syncytial Virus (RSV) Phase 2a Challenge Study. Am J Respir Crit Care Med 2018;197:A7715.
152. Kim YI, Pareek R, Murphy R, et al. The antiviral efects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin. Influenza Other Respir Viruses 2017;11:525-30. doi:10.1111/irv.12503
153. Karnik SC, Cook R, Gorman SH, Bakhtiar R. Liquid chromatographic-tandem mass spectrometry assay for the quantifcation of MDT-637 in human nasal wash. Biomed Chromatogr 2018;:e4271. doi:10.1002/bmc.4271
154. Challa S, Scott AD, Yuzhakov O, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother 2015;59:1080-7. doi:10.1128/AAC.04119-14
155. Novina CD, Sharp PA. The RNAi revolution. Nature 2004;430:161-4. doi:10.1038/430161a
156. Simon A, Karsten V, Cehelsky J, et al. Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients. Eur Respir J 2012;40(Suppl 56):1476.
157. Simões EAF, DeVincenzo J P, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 2015;211(Suppl 1):S1-20. doi:10.1093/infdis/jiu828
158. American Academy of Pediatrics Committee on Infectious DiseasesAmerican Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134:415-20. doi:10.1542/peds.2014-1665
159. Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011;11:1455-67. doi:10.1517/14712598.2011.608062
160. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection afer allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007;45:1019-24. doi:10.1086/521912
161. Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2010;12:38-44. doi:10.1111/j.1399-3062.2009.00453.x
162. Domachowske JB, Khan AA, Esser MT, et al. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Pediatr Infect Dis J 2018;37:886-92. doi:10.1097/INF.0000000000001916
163. Groothuis JR, Simoes EA, Hemming VGRespiratory Syncytial Virus Immune Globulin Study Group. Respiratory syncytial virus (RSV) infection in preterm infants and the protective efects of RSV immune globulin (RSVIG). Pediatrics 1995;95:463-7.
164. Simoes EA, Sondheimer HM, Top FHJr, et al, The Cardiac Study Group. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998;133:492-9. doi:10.1016/S0022-3476(98)70056-3
165. Cortez K, Murphy BR, Almeida KN, et al. Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis 2002;186:834-8. doi:10.1086/342412
166. Wasserman RL, Greener BN, Mond J. RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodefciency disease and other immune compromised populations. Expert Rev Clin Immunol 2017;13:1107-19. doi:10.1080/174466 6X.2017.1389647
167. Van Heeke G, Allosery K, De Brabandere V, et al. Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacol Ther 2017;169:47-56. doi:10.1016/j.pharmthera.2016.06.012
168. Larios Mora A, Detalle L, Gallup JM, et al. Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs. MAbs 2018;10:778-95. doi:10.1080/19420862.2 018.1470727
169. Healy CM. Vaccines in pregnant women and research initiatives. Clin Obstet Gynecol 2012;55:474-86. doi:10.1097/GRF.0b013e31824f3acb
170. Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol 2015;35:30-8. doi:10.1016/j. coi.2015.04.005
171. Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM. RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog 2015;11:e1004757. doi:10.1371/journal.ppat.1004757
172. Liang B, Ngwuta JO, Herbert R, et al. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. J Virol 2016;90:10022-38. doi:10.1128/JVI.01196-16
173. Johnson TR, Rangel D, Graham BS, Brough DE, Gall JG. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther 2014;22:196-205. doi:10.1038/mt.2013.142
174. Taylor G, Thom M, Capone S, et al. Efcacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci Transl Med 2015;7:300ra127. doi:10.1126/scitranslmed.aac5757
175. Widjojoatmodjo MN, Bogaert L, Meek B, et al. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Vaccine 2015;33:5406-14. doi:10.1016/j.vaccine.2015.08.056
176. Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-Amplifying RNA vaccines. Proc Natl Acad Sci USA 2012;109:14604-9. doi:10.1073/pnas.1209367109
177. Gilman MS, Castellanos CA, Chen M, et al. Rapid profling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol 2016;1:eaaj1879
178. Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S. Respiratory syncytial virus-specifc cell-mediated immune responses afer vaccination with a purifed fusion protein subunit vaccine. J Infect Dis 1994;170:425-8. doi:10.1093/infdis/170.2.425
179. McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013;342:592-8. doi:10.1126/science.1243283
180. Capella C, Chaiwatpongsakorn S, Gorrell E, et al. Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. J Infect Dis 2017;216:1398-406. doi:10.1093/infdis/jix489
181. Fedechkin SO, George NL, Wolf JT, et al. Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies. Sci Immunol 2018;3:eaar3534.
182. Amirthalingam G, Andrews N, Campbell H, et al. Efectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014;384:1521-8. doi:10.1016/S0140-6736(14)60686-3
183. Zaman K, Roy E, Arifeen SE, et al. Efectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64. doi:10.1056/NEJMoa0708630
184. Chu HY, Steinhof MC, Magaret A, et al. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 2014;210:1582-9. doi:10.1093/infdis/jiu316
185. Munoz FM, Piedra PA, Glezen W P. Safety and immunogenicity of respiratory syncytial virus purifed fusion protein-2 vaccine in pregnant women. Vaccine 2003;21:3465-7. doi:10.1016/S0264-410X(03)00352-9
186. Roberts JN, Graham BS, Karron RA, et al. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine 2016;34:4843-9. doi:10.1016/j. vaccine.2016.07.057
187. Raghunandan R, Lu H, Zhou B, et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine 2014;32:6485-92. doi:10.1016/j.vaccine.2014.09.030
188. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev 2014;35:519-30. doi:10.1542/pir.35-12-519
189. Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specifc antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 2015;7:309ra162-309ra162.